# Commission Decision of 23 August 2005 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2005 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2005) 333) (Only the Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Slovenian, Spanish and Swedish texts are authentic) (Text with EEA relevance) (2005/626/EC), Annex I

Extent: E+W+S+N.I.

Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:
Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country
Salbutamol
Terbutaline
Fenoterol
Orciprenaline
Reproterol
Carbuterol
Hexoprenaline
Pirbuterol
Clenbuterol
Bitolterol
Procaterol
Beclamethasone
Dexamethasone
Flunisolide
Fluticasone
Budesonide
Triamcinolone
Ipratropium bromide
Oxitropium bromide
Austria
Belgium
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Latvia
Lithuania
Luxembourg
Poland
Portugal
The Netherlands
Norway
Slovak Republic
Slovenia
Spain
Sweden
UK

---
Source: https://www.legislation.gov.uk/eudn/2005/626/annex/I (the official version)
Page: https://openlegislation.uk/eu-decision-2005-626/annex-I
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.